{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T07:08:13Z","timestamp":1771744093791,"version":"3.50.1"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,23]]},"DOI":"10.7759\/cureus.58866","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T04:09:07Z","timestamp":1713931747000},"source":"Crossref","is-referenced-by-count":3,"title":["Monkeypox: From Emerging Trends to Therapeutic Concerns"],"prefix":"10.7759","author":[{"given":"Kiran  G","family":"Piparva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nilesh","family":"Fichadiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tejal","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahenaz","family":"Malek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2018.00241","article-title":"Emergence of monkeypox as the most important orthopoxvirus infection in humans","volume":"6","author":"Sklenovsk\u00e1 N","year":"2018","unstructured":"Sklenovsk\u00e1 N, Van Ranst M. Emergence of monkeypox as the most important orthopoxvirus infection in humans. Front Public Health. 2018, 6:241. 10.3389\/fpubh.2018.00241","journal-title":"Front Public Health"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1699-0463.1959.tb00328.x","article-title":"A pox-like disease in cynomolgus monkeys","volume":"46","author":"Magnus VP","year":"1959","unstructured":"Magnus VP, Anderson EK, Petersen KB, Birch-Andersen A. A pox-like disease in cynomolgus monkeys. Acta Pathol Microbiol Scand. 1959, 46:156-76. 10.1111\/j.1699-0463.1959.tb00328.x","journal-title":"Acta Pathol Microbiol Scand"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1128\/br.37.1.1-18.1973","article-title":"Monkeypox virus","volume":"37","author":"Cho CT","year":"1973","unstructured":"Cho CT, Wenner HA. Monkeypox virus. Bacteriol Rev. 1973, 37:1-18. 10.1128\/br.37.1.1-18.1973","journal-title":"Bacteriol Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/17.3.643","article-title":"The transmission potential of monkeypox virus in human populations","volume":"10","author":"Fine PE","year":"1988","unstructured":"Fine PE, Jezek Z, Grab B, Dixon H. The transmission potential of monkeypox virus in human populations. Int J Epidemiol. 1988, 10:1093. 10.1093\/ije\/17.3.643","journal-title":"Int J Epidemiol"},{"key":"ref5","article-title":"A human infection caused by monkeypox virus in Basankusu Territory, Democratic Republic of the Congo","volume":"46","author":"Ladnyj ID","year":"1972","unstructured":"Ladnyj ID, Ziegler P, Kima E. A human infection caused by monkeypox virus in Basankusu Territory, Democratic Republic of the Congo. Bull World Health Organ. 1972, 46:593-7.","journal-title":"Bull World Health Organ"},{"key":"ref6","article-title":"Human monkeypox -- Kasai Oriental, Democratic Republic of Congo, February 1996-October 1997","volume":"46","year":"1997","unstructured":"Human monkeypox -- Kasai Oriental, Democratic Republic of Congo, February 1996-October 1997. MMWR Morb Mortal Wkly Rep. 1997, 46.1168-71.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1053\/j.spid.2004.09.001","article-title":"Monkeypox: a review of the history and emergence in the Western hemisphere","volume":"15","author":"Ligon BL","year":"2004","unstructured":"Ligon BL. Monkeypox: a review of the history and emergence in the Western hemisphere. Semin Pediatr Infect Dis. 2004, 15:280-7. 10.1053\/j.spid.2004.09.001","journal-title":"Semin Pediatr Infect Dis"},{"key":"ref8","unstructured":"Monkeypox treatment trial begins in the Democratic Republic of the Congo. (2022). Accessed. December, 02, 2023: https:\/\/www.nih.gov\/news-events\/news-releases\/monkeypox-treatment-trial-begins-democratic-republic-congo."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.10802","article-title":"Monkeypox in 2022-what clinicians need to know","volume":"328","author":"Guarner J","year":"2022","unstructured":"Guarner J, Del Rio C, Malani PN. Monkeypox in 2022-what clinicians need to know. JAMA. 2022, 328:139-40. 10.1001\/jama.2022.10802","journal-title":"JAMA"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.04.014","article-title":"Status of human monkeypox: clinical disease, epidemiology and research","volume":"29 Suppl 4","author":"Damon IK","year":"2011","unstructured":"Damon IK. Status of human monkeypox: clinical disease, epidemiology and research. Vaccine. 2011, 29 Suppl 4:D54-9. 10.1016\/j.vaccine.2011.04.014","journal-title":"Vaccine"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3201\/eid0703.010311","article-title":"Outbreak of human monkeypox, Democratic Republic of Congo, 1996 to 1997","volume":"7","author":"Hutin YJ","year":"2001","unstructured":"Hutin YJ, Williams RJ, Malfait P, et al.. Outbreak of human monkeypox, Democratic Republic of Congo, 1996 to 1997. Emerg Infect Dis. 2001, 7:434-8. 10.3201\/eid0703.010311","journal-title":"Emerg Infect Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/v9120380","article-title":"Improving the care and treatment of monkeypox patients in low-resource settings: applying evidence from contemporary biomedical and smallpox biodefense research","volume":"9","author":"Reynolds MG","year":"2017","unstructured":"Reynolds MG, McCollum AM, Nguete B, Shongo Lushima R, Petersen BW. Improving the care and treatment of monkeypox patients in low-resource settings: applying evidence from contemporary biomedical and smallpox biodefense research. Viruses. 2017, 9:10.3390\/v9120380","journal-title":"Viruses"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/v9100283","article-title":"Assessing monkeypox virus prevalence in small mammals at the human-animal interface in the Democratic Republic of the Congo","volume":"9","author":"Doty JB","year":"2017","unstructured":"Doty JB, Malekani JM, Kalemba LN, et al.. Assessing monkeypox virus prevalence in small mammals at the human-animal interface in the Democratic Republic of the Congo. Viruses. 2017, 9:10.3390\/v9100283","journal-title":"Viruses"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6710a5","article-title":"Emergence of monkeypox - West and Central Africa, 1970-2017","volume":"67","author":"Durski KN","year":"2018","unstructured":"Durski KN, McCollum AM, Nakazawa Y, et al.. Emergence of monkeypox - West and Central Africa, 1970-2017. MMWR Morb Mortal Wkly Rep. 2018, 67:306-10. 10.15585\/mmwr.mm6710a5","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.1.30","article-title":"Multistate outbreak of monkeypox\u2014 Illinois, Indiana, and Wisconsin, 2003","volume":"290","year":"2003","unstructured":"Multistate outbreak of monkeypox\u2014 Illinois, Indiana, and Wisconsin, 2003. JAMA. 2003, 290.30-31. 10.1001\/jama.290.1.30","journal-title":"JAMA"},{"key":"ref16","unstructured":"Monkeypox - United Kingdom of Great Britain and Northern Ireland. (2022). Accessed. May 20, 2022:  https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2022-DON381."},{"key":"ref17","unstructured":"Multi-country monkeypox outbreak. situation update. (2022). Accessed: December 31, 2023: https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2022-DON393."},{"key":"ref18","unstructured":"Second meeting of the International Health Regulations (2005) (IHR) Emergency Committee regarding the multi-country outbreak of monkeypox. (2022). Accessed. August 26, 2022: https:\/\/www.who.int\/news\/item\/23-07-2022-second-meeting-of-the-international-health-regulations-(2005)-(ihr)-emergenc...."},{"key":"ref19","unstructured":"WHO Director-General's statement at the press conference following IHR Emergency Committee regarding the multi-country outbreak of monkeypox - 23 July 2022. (2022). Accessed. September 29, 2022: https:\/\/www.who.int\/director-general\/speeches\/detail\/who-director-general-s-statement-on-the-press-conference-followi...."},{"key":"ref20","unstructured":"WHO director-general declares the ongoing monkeypox outbreak a public health emergency of international concern. (2022). Accessed. January 12, 2023: https:\/\/www.who.int\/europe\/news\/item\/23-07-2022-who-director-general-declares-the-ongoing-monkeypox-outbreak-a-public...."},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2207323","article-title":"Monkeypox virus infection in humans across 16 countries \u2014 April-June 2022","volume":"25","author":"Thornhill JP","year":"2022","unstructured":"Thornhill JP, Barkati S, Walmsley S, et al.. Monkeypox virus infection in humans across 16 countries \u2014 April-June 2022. N Engl J Med. 2022, 25:679-91. 10.1056\/NEJMoa2207323","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.o1489","article-title":"Monkeypox: WHO to rename disease to prevent stigma","volume":"377","author":"Taylor L","year":"2022","unstructured":"Taylor L. Monkeypox: WHO to rename disease to prevent stigma. BMJ. 2022, 377:o1489. 10.1136\/bmj.o1489","journal-title":"BMJ"},{"key":"ref23","unstructured":"2022-2023 mpox outbreak global map. (2023). Accessed. December 2, 2023: https:\/\/www.cdc.gov\/poxvirus\/mpox\/response\/2022\/world-map.html."},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmni.2022.101078","article-title":"Factors associated with geographic variations in the 2022 monkeypox outbreak; a systematic review","volume":"51","author":"Abu-Hammad O","year":"2023","unstructured":"Abu-Hammad O, Abu-Hammad A, Jaber AR, Jaber AR, Dar-Odeh N. Factors associated with geographic variations in the 2022 monkeypox outbreak; a systematic review. New Microbes New Infect. 2023, 51:101078. 10.1016\/j.nmni.2022.101078","journal-title":"New Microbes New Infect"},{"key":"ref25","unstructured":"Suspected monkeypox case found in Kerala, samples sent for testing. (2022). Accessed. October 7, 2022: https:\/\/www.news18.com\/news\/india\/suspected-monkeypox-case-found-in-kerala-samples-sent-for-testing-5551519.html."},{"key":"ref26","unstructured":"3 monkeypox sub-clusters found in India. ICMR study. (2022). Accessed: October 7, 2022: https:\/\/timesofindia.indiatimes.com\/india\/3-monkeypox-sub-clusters-found-in-india-icmr-study\/articleshow\/94274939.cms."},{"key":"ref27","unstructured":"2022-2023 mpox outbreak in India. (2022). Accessed. October 7, 2022: https:\/\/en.wikipedia.org\/w\/index.php?title=2022_monkeypox_outbreak_in_India&oldid=1111740712."},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(03)00856-9","article-title":"Human monkeypox: an emerging zoonosis","volume":"4","author":"Di Giulio DB","year":"2004","unstructured":"Di Giulio DB, Eckburg PB. Human monkeypox: an emerging zoonosis. Lancet Infect Dis. 2004, 4:15-25. 10.1016\/s1473-3099(03)00856-9","journal-title":"Lancet Infect Dis"},{"key":"ref29","unstructured":"Mpox (monkeypox). (2023). Accessed. December 2, 2023: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/monkeypox."},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/154.4.551","article-title":"Human monkeypox: a study of 2,510 contacts of 214 patients","volume":"154","author":"Jezek Z","year":"1986","unstructured":"Jezek Z, Marennikova SS, Mutumbo M, Nakano JH, Paluku KM, Szczeniowski M. Human monkeypox: a study of 2,510 contacts of 214 patients. J Infect Dis. 1986, 154:551-55. 10.1093\/infdis\/154.4.551","journal-title":"J Infect Dis"},{"key":"ref31","article-title":"Human monkeypox, 1970-79","volume":"58","author":"Breman JG","year":"1980","unstructured":"Breman JG, Kalisa-Ruti, Steniowski MV, Zanotto E, Gromyko AI, Arita I. Human monkeypox, 1970-79. Bull World Health Organ. 1980, 58:165-82.","journal-title":"Bull World Health Organ"},{"key":"ref32","article-title":"Human monkeypox","volume":"27","author":"Jezek Z","year":"1983","unstructured":"Jezek Z, Gromyko AI, Szczeniowski MV. Human monkeypox. J Hyg Epidemiol Microbiol Immunol. 1983, 27:13-28.","journal-title":"J Hyg Epidemiol Microbiol Immunol"},{"key":"ref33","unstructured":"Clinical recognition. key characteristics for identifying mpox. (2023). Accessed: December 31, 2023: https:\/\/www.cdc.gov\/poxvirus\/mpox\/clinicians\/clinical-recognition.html."},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00273-8","article-title":"Mpox in people with advanced HIV infection: a global case series","volume":"401","author":"Mitj\u00e0 O","year":"2023","unstructured":"Mitj\u00e0 O, Alemany A, Marks M, et al.. Mpox in people with advanced HIV infection: a global case series. Lancet. 2023, 401:939-49. 10.1016\/S0140-6736(23)00273-8","journal-title":"Lancet"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7209a4","article-title":"Interim clinical treatment considerations for severe manifestations of mpox - United States, February 2023","volume":"72","author":"Rao AK","year":"2023","unstructured":"Rao AK, Schrodt CA, Minhaj FS, et al.. Interim clinical treatment considerations for severe manifestations of mpox - United States, February 2023. MMWR Morb Mortal Wkly Rep. 2023, 72:232-43. 10.15585\/mmwr.mm7209a4","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref36","unstructured":"Guidelines for management of monkeypox disease. Accessed. August 26, 2022: https:\/\/main.mohfw.gov.in\/sites\/default\/files\/Guidelines%20for%20Management%20of%20Monkeypox%20Disease.pdf."},{"key":"ref37","article-title":"Treatment and prevention of mpox (monkeypox)","author":"Isaacs SN","year":"2024","unstructured":"Isaacs SN, Shenoy ES, Goldfarb IT. Treatment and prevention of mpox (monkeypox). UpToDate. Post TW (ed): UpToDate, Waltham, MA; 2024."},{"key":"ref38","unstructured":"Monkeypox. updates about clinical diagnosis and treatment. (2022). Accessed:  May 3, 2023: https:\/\/emergency.cdc.gov\/coca\/ppt\/2022\/062922_slides.pdf."},{"key":"ref39","unstructured":"Monkeypox in india. ICMR isolates virus; centre calls for vaccine, diagnostic kits to be developed. (2022). Accessed: December 2, 2023: https:\/\/www.india.com\/news\/india\/monkeypox-in-india-icmr-centremonkeypox-vaccine-update-diagnostic-kits-monkeypox-cas...."},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00228-6","article-title":"Clinical features and management of human monkeypox: a retrospective observational study in the UK","volume":"22","author":"Adler H","year":"2022","unstructured":"Adler H, Gould S, Hine P, et al.. Clinical features and management of human monkeypox: a retrospective observational study in the UK. Lancet Infect Dis. 2022, 22:1153-62. 10.1016\/S1473-3099(22)00228-6","journal-title":"Lancet Infect Dis"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7137e1","article-title":"Clinical use of tecovirimat (Tpoxx) for treatment of monkeypox under an investigational new drug protocol - United States, May-August 2022","volume":"71","author":"O'Laughlin K","year":"2022","unstructured":"O'Laughlin K, Tobolowsky FA, Elmor R, et al.. Clinical use of tecovirimat (Tpoxx) for treatment of monkeypox under an investigational new drug protocol - United States, May-August 2022. MMWR Morb Mortal Wkly Rep. 2022, 71:1190-5. 10.15585\/mmwr.mm7137e1","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2019.06.005","article-title":"The development and approval of tecoviromat (TPOXX\u00ae), the first antiviral against smallpox","volume":"168","author":"Merchlinsky M","year":"2019","unstructured":"Merchlinsky M, Albright A, Olson V, et al.. The development and approval of tecoviromat (TPOXX\u00ae), the first antiviral against smallpox. Antiviral Res. 2019, 168:168-74. 10.1016\/j.antiviral.2019.06.005","journal-title":"Antiviral Res"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1007\/s11030-023-10636-4","article-title":"Identification of FDA-approved drugs with triple targeting mode of action for the treatment of monkeypox: a high throughput virtual screening study","author":"Srivastava V","year":"2023","unstructured":"Srivastava V, Naik B, Godara P, Das D, Mattaparthi VS, Prusty D. Identification of FDA-approved drugs with triple targeting mode of action for the treatment of monkeypox: a high throughput virtual screening study. Mol Divers. 2023, 1-15. 10.1007\/s11030-023-10636-4","journal-title":"Mol Divers"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2210125","article-title":"Tecovirimat and the treatment of monkeypox - past, present, and future considerations","volume":"387","author":"Sherwat A","year":"2022","unstructured":"Sherwat A, Brooks JT, Birnkrant D, Kim P. Tecovirimat and the treatment of monkeypox - past, present, and future considerations. N Engl J Med. 2022, 387:579-81. 10.1056\/NEJMp2210125","journal-title":"N Engl J Med"},{"key":"ref45","unstructured":"Guidance for tecovirimat use. (2023). Accessed. December 3, 2023:  https:\/\/www.cdc.gov\/poxvirus\/monkeypox\/clinicians\/Tecovirimat.html."},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30788-6","article-title":"Assessing a drug for an eradicated human disease: US Food and Drug Administration review of tecovirimat for the treatment of smallpox","volume":"19","author":"Chan-Tack KM","year":"2019","unstructured":"Chan-Tack KM, Harrington PR, Choi S-Y, et al.. Assessing a drug for an eradicated human disease: US Food and Drug Administration review of tecovirimat for the treatment of smallpox. Lancet Infect Dis. 2019, 19:221-24. 10.1016\/S1473-3099(18)30788-6","journal-title":"Lancet Infect Dis"},{"key":"ref47","unstructured":"Tecovirimat SIGA. (2021). Accessed. January 3, 2023: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tecovirimat-siga."},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705688","article-title":"Oral tecovirimat for the treatment of smallpox","volume":"379","author":"Grosenbach DW","year":"2018","unstructured":"Grosenbach DW, Honeychurch K, Rose EA, et al.. Oral tecovirimat for the treatment of smallpox. N Engl J Med. 2018, 379:44-53. 10.1056\/NEJMoa1705688","journal-title":"N Engl J Med"},{"key":"ref49","article-title":"LiverTox: clinical and research information on drug-induced liver injury","year":"2022","unstructured":"LiverTox. clinical and research information on drug-induced liver injury. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD; 2022."},{"key":"ref50","unstructured":"Mpox. treatment information for healthcare professionals. (2022). Accessed: Septmeber 4, 2023: https:\/\/www.cdc.gov\/poxvirus\/monkeypox\/clinicians\/treatment.html."},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7132e4","article-title":"Interim guidance for prevention and treatment of monkeypox in persons with HIV infection - United States, August 2022","volume":"71","author":"O'Shea J","year":"2022","unstructured":"O'Shea J, Filardo TD, Morris SB, Weiser J, Petersen B, Brooks JT. Interim guidance for prevention and treatment of monkeypox in persons with HIV infection - United States, August 2022. MMWR Morb Mortal Wkly Rep. 2022, 71:1023-8. 10.15585\/mmwr.mm7132e4","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1144325","article-title":"Characterization of interventional clinical trials for monkeypox; systematic review of ClinicalTrials.gov database","volume":"11","author":"Alorfi NM","year":"2023","unstructured":"Alorfi NM, Alshehri FS, Haseeb A. Characterization of interventional clinical trials for monkeypox; systematic review of ClinicalTrials.gov database. Front Public Health. 2023, 11:1144325. 10.3389\/fpubh.2023.1144325","journal-title":"Front Public Health"},{"key":"ref53","unstructured":"U.S. clinical trial evaluating antiviral for monkeypox begins. (2022). Accessed. September 22, 2022: https:\/\/www.nih.gov\/news-events\/news-releases\/us-clinical-trial-evaluating-antiviral-monkeypox-begins."},{"key":"ref54","unstructured":"Study of tecovirimat for human monkeypox virus (STOMP). Accessed. December 2, 2023: https:\/\/clinicaltrials.gov\/study\/NCT05534984."},{"key":"ref55","unstructured":"Tecovirimat (TPOXX). Accessed. December 31, 2023: https:\/\/www.niaid.nih.gov\/diseases-conditions\/mpox-treatment#:~:text=Tecovirimat%20(TPOXX)&text=It%20is%20available%2...."},{"key":"ref56","unstructured":"Brincidofovir. Accessed. January 4, 2023: https:\/\/go.drugbank.com\/drugs\/DB12151."},{"key":"ref57","article-title":"Cidofovir: an overview","author":"Rodriguez M","year":"2024","unstructured":"Rodriguez M, Zachary KC. Cidofovir: an overview. UpToDate. Post TW (ed): UpToDate, Waltham, MA; 2024."},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2017.01.009","article-title":"Short-term clinical safety profile of brincidofovir: a favorable benefit-risk proposition in the treatment of smallpox","volume":"143","author":"Chittick G","year":"2017","unstructured":"Chittick G, Morrison M, Brundage T, Nichols WG. Short-term clinical safety profile of brincidofovir: a favorable benefit-risk proposition in the treatment of smallpox. Antiviral Res. 2017, 143:269-77. 10.1016\/j.antiviral.2017.01.009","journal-title":"Antiviral Res"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7142e1","article-title":"Ocular monkeypox - United States, July-September 2022","volume":"71","author":"Cash-Goldwasser S","year":"2022","unstructured":"Cash-Goldwasser S, Labuda SM, McCormick DW, et al.. Ocular monkeypox - United States, July-September 2022. MMWR Morb Mortal Wkly Rep. 2022, 71:1343-7. 10.15585\/mmwr.mm7142e1","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref60","article-title":"Antiviral agents","author":"Safrin S","year":"2015","unstructured":"Safrin S. Antiviral agents. Basic & Clinical Pharmacology. Katzung BG, Trevor AJ (ed): McGraw Hill, 2015. 835-65."},{"key":"ref61","doi-asserted-by":"crossref","DOI":"10.1542\/peds.18.2.177","article-title":"Hyperimmune vaccinal gamma globulin: source, evaluation, and use in prophylaxis and therapy","volume":"18","author":"Kempe CH","year":"1956","unstructured":"Kempe CH, Berge TO, England B. Hyperimmune vaccinal gamma globulin: source, evaluation, and use in prophylaxis and therapy. Pediatrics. 1956, 18:177-88.","journal-title":"Pediatrics"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.3390\/v2102381","article-title":"Therapeutic vaccines and antibodies for treatment of orthopoxvirus infections","volume":"2","author":"Xiao Y","year":"2010","unstructured":"Xiao Y, Isaacs SN. Therapeutic vaccines and antibodies for treatment of orthopoxvirus infections. Viruses. 2010, 2:2381-403. 10.3390\/v2102381","journal-title":"Viruses"},{"key":"ref63","doi-asserted-by":"crossref","DOI":"10.1542\/peds.26.2.176","article-title":"Studies on smallpox and complications of smallpox vaccination","volume":"26","author":"Kempe CH","year":"1960","unstructured":"Kempe CH . Studies on smallpox and complications of smallpox vaccination. Pediatrics. 1960, 26:176-89.","journal-title":"Pediatrics"},{"key":"ref64","unstructured":"CNJ-016 (vaccinia immune globulin- human injection). Accessed. December 21, 2023: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=a4f9f620-e6e4-4a03-a9a7-79007c8c2cfe."},{"key":"ref65","unstructured":"Poxvirus. (2020). Accessed. January 12, 2023: https:\/\/www.cdc.gov\/poxvirus\/index.html."},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-9-5","article-title":"In vitro inhibition of monkeypox virus production and spread by Interferon-\u03b2. Virol J. 2012;9:5.","volume":"6","author":"Johnston SC","year":"2012","unstructured":"Johnston SC, Lin KL, Connor JH, et al.. In vitro inhibition of monkeypox virus production and spread by Interferon-\u03b2. Virol J. 2012;9:5. . 2012, 6:9:5. 10.1186\/1743-422X-9-5"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.19.242347","article-title":"Modelling human-to-human transmission of monkeypox","volume":"98","author":"Grant R","year":"2020","unstructured":"Grant R, Nguyen LL, Breban R. Modelling human-to-human transmission of monkeypox. Bull World Health Organ. 2020, 98:638-40. 10.2471\/BLT.19.242347","journal-title":"Bull World Health Organ"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1005769107","article-title":"Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo","volume":"107","author":"Rimoin AW","year":"2010","unstructured":"Rimoin AW, Mulembakani PM, Johnston SC, et al.. Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc Natl Acad Sci U S A. 2010, 107:16262-7. 10.1073\/pnas.1005769107","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref69","unstructured":"Emergency purchase of monkeypox vaccine on hold. (2022). Accessed. January 12, 2023: https:\/\/www.hindustantimes.com\/india-news\/emergency-purchase-of-monkeypox-vaccine-on-hold-101662317542985.html."},{"key":"ref70","unstructured":"Monkeypox vaccine. when will it be rolled out in India?. (2022). Accessed: January 12, 2023: https:\/\/www.dnaindia.com\/health\/report-monkeypox-vaccine-when-will-it-be-rolled-out-in-india-who-will-get-it-first-29...."},{"key":"ref71","unstructured":"Mpox (monkeypox) vaccines. (2022). Accessed. January 12, 2023: https:\/\/www.health.gov.au\/diseases\/mpox-monkeypox\/vaccines."},{"key":"ref72","unstructured":"Interim clinical considerations for use of JYNNEOS and ACAM2000 vaccines during the 2022 U.S. mpox outbreak. Accessed. January 12, 2023: https:\/\/www.cdc.gov\/poxvirus\/mpox\/clinicians\/vaccines\/vaccine-considerations.html."},{"key":"ref73","unstructured":"JYNNEOS. Accessed. January 12, 2023: https:\/\/www.fda.gov\/vaccines-blood-biologics\/jynneos."},{"key":"ref74","unstructured":"As monkeypox threat grows, scientists debate best vaccine strategy. (2022). Accessed. December 3, 2023: https:\/\/www.science.org\/content\/article\/monkeypox-threat-grows-scientists-debate-best-vaccine-strategy."},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817307","article-title":"Phase 3 efficacy trial of modified vaccinia Ankara as a vaccine against smallpox","volume":"14","author":"Pittman PR","year":"2019","unstructured":"Pittman PR, Hahn M, Lee HS, et al.. Phase 3 efficacy trial of modified vaccinia Ankara as a vaccine against smallpox. N Engl J Med. 2019, 14:1897-908. 10.1056\/NEJMoa1817307","journal-title":"N Engl J Med"},{"key":"ref76","unstructured":"Clinical considerations for mpox in people who are pregnant or breastfeeding. (2023). Accessed. December 3, 2023: https:\/\/www.cdc.gov\/poxvirus\/mpox\/clinicians\/pregnancy.html#:~:text=Mpox%20and%20Pregnancy,-Data%20regarding%20mpox&t...."},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00270-0","article-title":"Early evaluation of the safety, reactogenicity, and immune response after a single dose of modified vaccinia Ankara-Bavaria Nordic vaccine against mpox in children: a national outbreak response","volume":"23","author":"Ladhani SN","year":"2023","unstructured":"Ladhani SN, Dowell AC, Jones S, et al.. Early evaluation of the safety, reactogenicity, and immune response after a single dose of modified vaccinia Ankara-Bavaria Nordic vaccine against mpox in children: a national outbreak response. Lancet Infect Dis. 2023, 23:1042-50. 10.1016\/S1473-3099(23)00270-0","journal-title":"Lancet Infect Dis"},{"key":"ref78","unstructured":"Notice to readers. newly licensed smallpox vaccine to replace old smallpox vaccine. (2008). Accessed: January 12, 2023: https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm5708a6.htm."},{"key":"ref79","unstructured":"Smallpox. contraindications to vaccination. (2016). Accessed: December 3, 2023: https:\/\/www.cdc.gov\/smallpox\/clinicians\/vaccination-contraindications1.html."},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00527-4","article-title":"Current status of monkeypox vaccines","volume":"7","author":"Gruber MF","year":"2022","unstructured":"Gruber MF. Current status of monkeypox vaccines. NPJ Vaccines. 2022, 7:94. 10.1038\/s41541-022-00527-4","journal-title":"NPJ Vaccines"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2300290","article-title":"Mpox neutralizing antibody response to LC16m8 vaccine in healthy adults","volume":"3","author":"Morino E","year":"2024","unstructured":"Morino E, Mine S, Tomita N, et al.. Mpox neutralizing antibody response to LC16m8 vaccine in healthy adults. NEJM Evid. 2024, 3:EVIDoa2300290. 10.1056\/EVIDoa2300290","journal-title":"NEJM Evid"},{"key":"ref82","unstructured":"Vaccines and immunization for monkeypox. Interim guidance, 16 November 2022. (2022). Accessed: December 3, 2023: https:\/\/www.who.int\/publications\/i\/item\/WHO-MPX-Immunization."},{"key":"ref83","unstructured":"ACIP recommendations. (2023). Accessed. December 10, 2023: https:\/\/www.cdc.gov\/vaccines\/acip\/recommendations.html."},{"key":"ref84","unstructured":"Smallpox\/monkeypox vaccine information statement. (2022). Accessed. April 23, 2024: https:\/\/www.cdc.gov\/vaccines\/hcp\/vis\/vis-statements\/smallpox-monkeypox.html."},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1086\/498155","article-title":"Reemergence of monkeypox: prevalence, diagnostics, and countermeasures","volume":"41","author":"Nalca A","year":"2005","unstructured":"Nalca A, Rimoin AW, Bavari S, Whitehouse CA. Reemergence of monkeypox: prevalence, diagnostics, and countermeasures. Clin Infect Dis. 2005, 41:1765-71. 10.1086\/498155","journal-title":"Clin Infect Dis"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2017.02196","article-title":"Suppression of poxvirus replication by resveratrol","volume":"8","author":"Cao S","year":"2017","unstructured":"Cao S, Realegeno S, Pant A, Satheshkumar PS, Yang Z. Suppression of poxvirus replication by resveratrol. Front Microbiol. 2017, 8:2196. 10.3389\/fmicb.2017.02196","journal-title":"Front Microbiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/224500-monkeypox-from-emerging-trends-to-therapeutic-concerns","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T04:09:26Z","timestamp":1713931766000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/224500-monkeypox-from-emerging-trends-to-therapeutic-concerns"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,23]]},"references-count":86,"URL":"https:\/\/doi.org\/10.7759\/cureus.58866","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,23]]}}}